Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
Maria Gabriella Matera,1 Alessandro Sanduzzi,2 Mario Cazzola3 1Department of Experimental Medicine, Second University of Naples, 2Department of Respiratory Diseases, Monaldi Hospital, University Federico II, Naples, 3Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy Abstr...
Main Authors: | Matera MG, Sanduzzi A, Cazzola M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-01-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/specific-role-of-combination-aclidinium-formoterol-in-the-treatment-of-peer-reviewed-article-COPD |
Similar Items
-
New combinations in the treatment of COPD: rationale for aclidinium–formoterol
by: Incorvaia C, et al.
Published: (2016-02-01) -
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
by: D'Urzo AD, et al.
Published: (2019-02-01) -
The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
by: Miravitlles M, et al.
Published: (2016-08-01) -
ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
by: Watz H, et al.
Published: (2017-08-01) -
12-Hour fixed-dose combination of andrenergic agonist and cholinergic antagonist in a new administration device: analytical review
by: A. A. Vizel, et al.
Published: (2018-10-01)